Baxter Presents at BofA Conference; No Shift in Bearish Outlook

What happened

Baxter management presented at the Bank of America Global Healthcare Conference 2026, reiterating their deleveraging and operational turnaround strategy. The presentation offered no material new information beyond what was already disclosed in recent filings and earnings calls. The company continues to face significant headwinds from high leverage, negative free cash flow, and unresolved product issues, particularly the Novum IQ pump recall. The market's muted reaction reflects that the narrative remains centered on balance-sheet repair rather than growth. Our analysis sees no catalyst to change the current cautious stance.

Implication

The conference presentation offered no substantive updates that would change our negative assessment. Baxter’s debt-heavy balance sheet and weak operational momentum persist, with net leverage above 4x and free cash flow still negative year-to-date. The company’s essential product portfolio provides some downside protection, but the margin of safety is insufficient given ongoing execution risks around the Novum IQ recall and IV fluid demand normalization. Until 2026 guidance or Q4 results demonstrate credible progress toward positive FCF and debt reduction, the risk-reward remains unattractive. Investors should maintain a sell-side disposition and look for concrete improvements in financial and product metrics before re-engaging.

Thesis delta

The Bank of America presentation did not introduce any new financial targets or operational milestones beyond those already disclosed. Therefore, our thesis remains unchanged: Baxter’s weak cash generation, high leverage, and unresolved product issues outweigh potential benefits from deleveraging and margin improvement. The stock continues to be a hold or sell in our view, with a $22 base case implying limited upside from current levels.